Is DNLI a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on AVLAYAH commercial launch, with revenue (ttm) at ~$3.6M, all from Q2 2026, the first AVLAYAH quarter. The bear case rests on denali remains deeply unprofitable, posting net losses of roughly $128 million in each of Q1 and Q2 2026 (about $511 million over the trailing twelve months), with Q2 EPS of -$0.68 well short of the -$0.47 consensus, with heavy ongoing R&D spend, so it depends on its cash balance, partnerships, and future financings. Analysts covering it are spread from $27.00 to $42.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Denali remains deeply unprofitable, posting net losses of roughly $128 million in each of Q1 and Q2 2026 (about $511 million over the trailing twelve months), with Q2 EPS of -$0.68 well short of the -$0.47 consensus, with heavy ongoing R&D spend, so it depends on its cash balance, partnerships, and future financings. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $27.00, +53.3% from the $17.61 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

AVLAYAH commercial launch. AVLAYAH is Denali's first approved product and its first potential recurring revenue stream, launched in the U.S. The most optimistic analyst target on DNLI is $42.00, +138.5% from the $17.61 price. That figure is only reachable if this thesis works close to its best case.

Denali remains deeply unprofitable, posting net losses of roughly $128 million in each of Q1 and Q2 2026 (about $511 million over the trailing twelve months), with Q2 EPS of -$0.68 well short of the -$0.47 consensus, with heavy ongoing R&D spend, so it depends on its cash balance, partnerships, and future financings. AVLAYAH targets a very small patient population, meaning near-term revenue could ramp slowly and disappoint if diagnosis or reimbursement lags. Accelerated approval carries a confirmatory-evidence obligation, and clinical setbacks are a live risk given the discontinued ALS program. The broader neuro pipeline is early and high-failure-rate, competition from Takeda and gene-therapy developers is real, and the stock is volatile and driven by binary catalysts. Launch expectations are now baked into estimates: consensus calls for about $131 million of revenue in 2027, so a slow Q3 or Q4 ramp would land against a specific bar. The most pessimistic published target is $27.00, +53.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Denali Therapeutics (NASDAQ: DNLI) is a South San Francisco biotechnology company built around its proprietary Transport Vehicle (TV) platform, an engineered antibody-fragment tech

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AVLAYAH commercial launch) stalling in the reported numbers rather than in the narrative, the risk above (denali remains deeply unprofitable, posting net losses of roughly $128 million in each of Q1 and Q2 2026 (about $511 million over the trailing twelve months), with Q2 EPS of -$0.68 well short of the -$0.47 consensus, with heavy ongoing R&D spend, so it depends on its cash balance, partnerships, and future financings) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Denali is a biotechnology company developing therapies for neurodegenerative and lysosomal storage diseases. Its core asset is the Transport Vehicle platform, which engineers drugs to cross the blood-brain barrier so they can reach the brain after an IV infusion.

No. Denali is not profitable and reported net losses of roughly $128 million in each of Q1 and Q2 2026, about $511 million over the twelve months to June 2026, on heavy research and development spending. Its first product launched in April 2026 and produced about $3.6 million of revenue in Q2, so it is early in generating product revenue.

AVLAYAH (tividenofusp alfa-eknm) is Denali's first FDA-approved product, granted accelerated approval in March 2026 for the neurologic manifestations of Hunter syndrome (MPS II). It is a once-weekly enzyme replacement therapy and the first in its class designed to reach the brain.